| Obinutuzumab for the first-line treatment of follicular lymphoma R Marcus, A Davies, K Ando, W Klapper, S Opat, C Owen, E Phillips, ... New England Journal of Medicine 377 (14), 1331-1344, 2017 | 745 | 2017 |
| Hodgkin's lymphoma in adults W Townsend, D Linch The Lancet 380 (9844), 836-847, 2012 | 244 | 2012 |
| Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma M Hamadani, J Radford, C Carlo-Stella, PF Caimi, E Reid, OA O’Connor, ... Blood, The Journal of the American Society of Hematology 137 (19), 2634-2645, 2021 | 150 | 2021 |
| De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United … PA Fields, W Townsend, A Webb, N Counsell, C Pocock, P Smith, A Jack, ... Journal of clinical oncology 32 (4), 282-287, 2014 | 115 | 2014 |
| A national service for delivering CD19 CAR‐T in large B‐cell lymphoma–The UK real‐world experience A Kuhnl, C Roddie, AA Kirkwood, E Tholouli, T Menne, A Patel, C Besley, ... British Journal of Haematology 198 (3), 492-502, 2022 | 75 | 2022 |
| Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning WM Townsend, A Holroyd, R Pearce, S Mackinnon, P Naik, AH Goldstone, ... British journal of haematology 161 (4), 578-586, 2013 | 70 | 2013 |
| Obinutuzumab-based induction and maintenance prolongs progression-free survival (PFS) in patients with previously untreated follicular lymphoma: primary results of the … RE Marcus, AJ Davies, K Ando, W Klapper, S Opat, CJ Owen, EH Phillips, ... Blood 128 (22), 6, 2016 | 67 | 2016 |
| Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma C Roddie, L Neill, W Osborne, S Iyengar, E Tholouli, D Irvine, S Chaganti, ... Blood Advances 7 (12), 2872-2883, 2023 | 56 | 2023 |
| Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma A Kuhnl, C Roddie, AA Kirkwood, T Menne, M Cuadrado, MAV Marzolini, ... Blood advances 6 (1), 321, 2022 | 50 | 2022 |
| Positron emission tomography score has greater prognostic significance than pretreatment risk stratification in early-stage Hodgkin lymphoma in the UK RAPID study SF Barrington, EH Phillips, N Counsell, B Hancock, R Pettengell, ... Journal of Clinical Oncology 37 (20), 1732-1741, 2019 | 46 | 2019 |
| Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups T Marafioti, C Copie‐Bergman, M Calaminici, JC Paterson, VH Shende, ... Histopathology 62 (6), 860-875, 2013 | 43 | 2013 |
| Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular lymphoma: initial … F Morschhauser, M Bishton, TA Eyre, E Bachy, G Cartron, L Ysebaert, ... Blood 138, 129, 2021 | 28 | 2021 |
| Guideline for the first‐line management of Classical Hodgkin Lymphoma—A British Society for Haematology guideline GA Follows, SF Barrington, KS Bhuller, DJ Culligan, DJ Cutter, ... British journal of haematology 197 (5), 558-572, 2022 | 26 | 2022 |
| The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells W Townsend, M Pasikowska, D Yallop, EH Phillips, PEM Patten, ... Haematologica 105 (6), 1593, 2020 | 26 | 2020 |
| Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL M Northend, W Wilson, W Osborne, CP Fox, AJ Davies, D El-Sharkawi, ... Blood advances 6 (9), 2920-2926, 2022 | 25 | 2022 |
| Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial AF Herrera, C Burton, J Radford, F Miall, W Townsend, A Santoro, ... Blood Advances 5 (17), 3387-3396, 2021 | 24 | 2021 |
| Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma … SER Halford, H Walter, P McKay, W Townsend, K Linton, K Heinzmann, ... Journal of Clinical Oncology 39 (15_suppl), 3115-3115, 2021 | 24 | 2021 |
| CD20-TCB, a novel T-cell-engaging bispecific antibody, can be safely combined with the anti-PD-L1 antibody atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma M Hutchings, G Gritti, A Sureda, MJ Terol, MJS Dyer, G Iacoboni, ... Blood 134, 2871, 2019 | 24 | 2019 |
| Update: the investigation and management of follicular lymphoma C McNamara, S Montoto, TA Eyre, K Ardeshna, C Burton, TM Illidge, ... | 22 | 2020 |
| Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID‐19 with B‐cell malignancies TA Fox, AA Kirkwood, L Enfield, M O'Reilly, S Arulogun, S D'Sa, J O'Nions, ... British Journal of Haematology 195 (5), 706, 2021 | 19 | 2021 |
